INEX INNOVATE PRIVATE LTD.
Company Snapshot
Company Overview
Founded in 2006, Inex Innovations Exchange Pte. Ltd. develops molecular diagnostic tests related to women’s health. The focus is on noninvasive prenatal testing, same-day prenatal diagnosis, and ovarian cancer diagnosis and screening.
Inex’s iGene is an NGS-based NIPT that detects chromosomal abnormalities, including trisomies 21, 18 and 13. iGene analyzes a mix of maternal and fetal DNA in maternal blood. The test is offered through iGene Diagnostics, a subsidiary of Inex, and runs on the Thermo Fisher Ion Proton platform.
In 2017, Inex exclusively licensed NIPT technology from A-Star (Singapore Agency for Science, Technology, and Research). This technology covered the isolation and genetic analysis of circulating fetal cells from maternal blood.
Additional tests marketed by Inex that are non-NGS driven include OvaCis (colorimetric assay) for detecting ovarian cancer and FlashFISH (fluorescence in situ hybridization) for rapid analysis of amniocentesis samples.
Company's Business Segments
- Molecular Diagnostics : INEX Innovate is constantly innovating to address valuable clinical unmet needs with Diagnostic Test Offerings, and has developed a broad range of IP.
Applications/End User Industries
- Clinical Research
- Academic Research
- Biotechnology
- Healthcare
- Women's Health
- Molecular Diagnostics
- Pharmaceutical
